Intuitive Surgical's Growth Deceleration Splits Investors Even as a Swedish Pension Fund Goes Against the Grain
Published on 07/21/2026 at 17:14 | Redaktion boerse-global.de
Intuitive Surgical's stock has been hammered in 2026, losing more than 36% of its value and trading within 4% of a fresh 52-week low. The selloff has continued despite the company repeatedly beating earnings estimates, raising a central question for investors: if the numbers are so good, why won't the stock cooperate?
The answer became clearer on 16 July, when the da Vinci robot maker reported second-quarter results that topped forecasts on the top line but revealed a conspicuous slowdown in the US market. Revenue climbed 19% year-on-year to $2.89 billion, roughly 2.5% above analyst expectations. All three business segments contributed: instruments and accessories rose 18% to $1.73 billion, systems jumped 19% to $685 million on shipments of 468 da Vinci systems (versus 444 expected), and services added 21% to $472 million. Yet the stock sold off sharply on the day the numbers were released.
The culprit was US procedure growth. The metric came in at 11.5%, down from 13.5% in the first quarter and well short of the consensus estimate of 13.2%. Management pointed to two factors: changes in health-insurance coverage under the Affordable Care Act that are limiting patient access, and the law of large numbers — as the installed base grows, maintaining percentage gains becomes harder. The market interpreted the deceleration as a signal that the company's premium valuation may no longer be justified.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
What truly rattled Wall Street, however, was the guidance. Management merely reaffirmed the middle of its existing range of 13.5% to 15.5% for global da Vinci procedure growth in 2026. After a quarter that handily beat expectations, investors expected the floor to be raised. By leaving the forecast untouched, Intuitive Surgical effectively pencilled in slower growth for the remainder of the year — and the stock reacted accordingly.
Analyst reaction has been a study in cautious recalibration rather than outright panic. Multiple banks trimmed their price targets while keeping positive ratings. Bernstein SocGen Group cut its target from $750 to $685 but maintained Outperform and actually raised its 2027 earnings-per-share estimate by 4% to $12.71. Citi lowered its target to $500 and stuck with Buy. JPMorgan went to $450, and Mizuho slashed its target to $400 and downgraded the stock to Hold. William Blair kept its Outperform rating, describing the post-earnings selloff of more than 10% as an overreaction driven by inflated expectations rather than a structural deterioration. The consensus of targets remains well above the current share price, but the wide dispersion — from $400 to $685 — underscores the uncertainty about how much of the slowdown is temporary.
Into this environment stepped one of Sweden's national pension funds. Andra AP fonden boosted its stake in Intuitive Surgical by 139.7% in the first quarter, acquiring enough shares to hold 50,050 shares worth approximately $23.1 million. The move looks like a contrarian bet: the fund accumulated its position as the stock was already declining, and the share price has fallen further since. But not everyone close to the company shares that optimism. In early June, Senior Vice President Iman Jeddi sold 5,625 shares at $420.55 apiece, and Executive Vice President Gary Loeb sold 400 shares at $424.14 a week later. Both sales took place at levels far above today's trading range, suggesting that internal confidence has not yet returned despite the institutional buying.
The first quarter had already set a high bar: earnings per share of $2.50 blew past the $2.08 consensus, while revenue increased 23% to $2.77 billion. That strength carried into the second quarter, yet the market's attention remains fixed on the procedural-growth trajectory and the unchanged guidance. The relative strength index sits at 34.8, a technically oversold reading that often precedes a bounce but guarantees nothing. With annualized volatility above 54%, the stock remains a battleground between believers in the long-term robotics story and those who see the growth deceleration as an overdue correction. The pension fund's big bet and the analysts' guarded price targets offer two very different verdicts on which view will prevail.
Ad
Intuitive Surgical Stock: New Analysis - 21 July
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
